Literature DB >> 19107383

The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States.

J R Curtis1, A Laster, D J Becker, L Carbone, L C Gary, M L Kilgore, R S Matthews, M A Morrisey, K G Saag, S B Tanner, E Delzell.   

Abstract

UNLABELLED: Using national Medicare data from 1999-2006, we evaluated the relationship between travel distance and receipt of dual-energy X-ray absorptiometry (DXA). After adjusting for potentially confounding factors, travel distance was strongly associated with DXA testing. Rural residents were most strongly dependent on the availability of DXAs performed in physician offices.
INTRODUCTION: Medicare reimbursement for DXAs performed in non-facility settings (e.g., physician offices) decreased in 2007. With declining reimbursement, some DXA providers may cease providing this service, which would increase travel distance for some people. The impact of travel distance on access to DXA is unclear.
METHODS: Using national Medicare data, we identified claims for DXA to evaluate trends in the number and locations of DXAs performed. Travel distance was the distance from beneficiaries' residence and the nearest DXA provider. Binomial regression evaluated the relationship between travel distance and receipt of DXA.
RESULTS: In 2006, 2.9 million DXAs were performed, a 103% increase since 1999. In 2005-2006, 8.0% of persons were tested at non-facility sites versus 4.2% at facility sites. The remainder (88%) had no DXA. Persons traveling 5-9, 10-24, 25-39, and 40-54, and > or = 55 miles were less likely to receive DXA (adjusted risk ratios = 0.92, 0.79, 0.43, 0.32, and 0.26, respectively, < 5 miles referent). Rural residents were more dependent than urban residents on the availability of DXA from non-facility providers.
CONCLUSION: Approximately two-thirds of DXAs in 2005-2006 were performed in non-facility settings (e.g., physician offices). Rural residents would have preferentially reduced access to DXA if there were fewer non-facility sites.

Entities:  

Mesh:

Year:  2008        PMID: 19107383      PMCID: PMC2728788          DOI: 10.1007/s00198-008-0821-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  18 in total

1.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

2.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

3.  Access to bone mineral density testing in patients at risk for osteoporosis.

Authors:  D H Solomon; J M Polinski; C Truppo; C Egan; S Jan; M Patel; T W Weiss; Y T Chen; M A Brookhart
Journal:  Osteoporos Int       Date:  2006-07-20       Impact factor: 4.507

4.  Association between screening for osteoporosis and the incidence of hip fracture.

Authors:  Lisa M Kern; Neil R Powe; Michael A Levine; Annette L Fitzpatrick; Tamara B Harris; John Robbins; Linda P Fried
Journal:  Ann Intern Med       Date:  2005-02-01       Impact factor: 25.391

5.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

6.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

7.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

8.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

9.  Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries.

Authors:  Jeffrey R Curtis; Andrew J Laster; David J Becker; Laura Carbone; Lisa C Gary; Meredith L Kilgore; Robert Matthews; Michael A Morrisey; Kenneth G Saag; S Bobo Tanner; Elizabeth Delzell
Journal:  J Clin Densitom       Date:  2008-09-12       Impact factor: 2.617

10.  Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables.

Authors:  M McClellan; B J McNeil; J P Newhouse
Journal:  JAMA       Date:  1994-09-21       Impact factor: 56.272

View more
  20 in total

1.  Predictors of bone mineral density testing among older women on Medicare.

Authors:  Y Lou; S W Edmonds; M P Jones; F Ullrich; G L Wehby; P Cram; F D Wolinsky
Journal:  Osteoporos Int       Date:  2016-06-30       Impact factor: 4.507

2.  Effect of self-referral on bone mineral density testing and osteoporosis treatment.

Authors:  Amy H Warriner; Ryan C Outman; Adrianne C Feldstein; Douglas W Roblin; Jeroan J Allison; Jeffrey R Curtis; David T Redden; Mary M Rix; Brandi E Robinson; Ana G Rosales; Monika M Safford; Kenneth G Saag
Journal:  Med Care       Date:  2014-08       Impact factor: 2.983

3.  Digital X-ray radiogrammetry in the study of osteoporotic fractures: Comparison to dual energy X-ray absorptiometry and FRAX.

Authors:  Johan Kälvesten; Li-Yung Lui; Torkel Brismar; Steven Cummings
Journal:  Bone       Date:  2016-02-24       Impact factor: 4.398

Review 4.  Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies.

Authors:  John A Batsis; Dennis T Villareal
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

5.  Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study.

Authors:  K H Rubin; B Abrahamsen; A P Hermann; M Bech; J Gram; K Brixen
Journal:  Osteoporos Int       Date:  2010-08-04       Impact factor: 4.507

6.  Fracture risk assessment without bone density measurement in routine clinical practice.

Authors:  W D Leslie; S Morin; L M Lix; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

7.  A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.

Authors:  Amy H Warriner; Ryan C Outman; Elizabeth Kitchin; Lang Chen; Sarah Morgan; Kenneth G Saag; Jeffrey R Curtis
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

8.  Osteoporosis care in the United States after declines in reimbursements for DXA.

Authors:  Burton L Hayes; Jeffrey R Curtis; Andrew Laster; Kenneth Saag; S Bobo Tanner; Caiqin Liu; Catherine Womack; Karen C Johnson; Fazila Khaliq; Laura D Carbone
Journal:  J Clin Densitom       Date:  2010 Oct-Dec       Impact factor: 2.617

9.  Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.

Authors:  Maria E Suarez-Almazor; Prashanth Peddi; Ruili Luo; Hoang T Nguyen; Linda S Elting
Journal:  Support Care Cancer       Date:  2013-10-22       Impact factor: 3.603

10.  Utility of heel dual-energy X-ray absorptiometry in diagnosing osteoporosis.

Authors:  Sharon H Chou; Jessica Hwang; Siu-Ling Ma; Tamara Vokes
Journal:  J Clin Densitom       Date:  2013-10-19       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.